A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy

NCT06945107 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

308

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: Picankibart
DRUG: Secukinumab
DRUG: Placebo
DRUG: Ixekizumab

Sponsor

Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.